InnoCan Pharma (IP40) Stock Statistics & Valuation Metrics
Total Valuation
InnoCan Pharma has a market cap or net worth of EUR 5.48M. The enterprise value is EUR 8.16M.
- Market Cap
- EUR 5.48M
- Enterprise Value
- EUR 8.16M
Share Statistics
InnoCan Pharma has 4,498,772 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,498,772
- Owned by Insiders
- 0.88%
- Owned by Institutions
- ―
Financial Efficiency
InnoCan Pharma’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is 54.92%.
- Return on Equity (ROE)
- -0.20
- Return on Assets (ROA)
- -0.11
- Return on Invested Capital (ROIC)
- 54.92%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 2.42M
- Profits Per Employee
- -102.18K
- Employee Count
- 11
- Asset Turnover
- 2.53
- Inventory Turnover
- 1.23
Valuation Ratios
The current PE Ratio of InnoCan Pharma is -6.55. InnoCan Pharma’s PEG ratio is 0.06.
- PE Ratio
- -6.55
- PS Ratio
- 0.26
- PB Ratio
- 1.28
- Price to FCF
- -3.97
- Price to Operating Cash Flow
- -4.02
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 26.61M and earned -1.12M in profits. Earnings per share was -0.25.
- Revenue
- 26.61M
- Gross Profit
- 23.93M
- Operating Income
- -1.25M
- Pretax Income
- 85.00K
- Net Income
- -1.12M
- EBITDA
- 130.00K
- Earnings Per Share (EPS)
- -0.25
Cash Flow
In the last 12 months, operating cash flow was -1.52M and capital expenditures -19,015, giving a free cash flow of -1.54M billion.
- Operating Cash Flow
- -1.52M
- Free Cash Flow
- -1.54M
- Free Cash Flow per Share
- -0.34
Dividends & Yields
InnoCan Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -25.22%
- Earnings Yield
- -15.41%
Stock Price Statistics
- Beta
- -0.45
- 52-Week Price Change
- -90.30%
- 50-Day Moving Average
- 1.28
- 200-Day Moving Average
- 2.61
- Relative Strength Index (RSI)
- 40.43
- Average Volume (3m)
- 424
Important Dates
InnoCan Pharma upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Financial Position
InnoCan Pharma as a current ratio of 7.70, with Debt / Equity ratio of 16.61%
- Current Ratio
- 7.70
- Quick Ratio
- 6.09
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- -44.28
- Interest Coverage Ratio
- -418.33
Taxes
In the past 12 months, InnoCan Pharma has paid 426.00K in taxes.
- Income Tax
- 426.00K
- Effective Tax Rate
- 5.01
Enterprise Valuation
InnoCan Pharma EV to EBITDA ratio is -1.23, with an EV/FCF ratio of -0.87.
- EV to Sales
- 0.06
- EV to EBITDA
- -1.23
- EV to Free Cash Flow
- -0.87
- EV to Operating Cash Flow
- -0.88
Balance Sheet
InnoCan Pharma has EUR 6.44M in cash and marketable securities with EUR 1.66M in debt, giving a net cash position of EUR 4.78M billion.
- Cash & Marketable Securities
- EUR 6.44M
- Total Debt
- EUR 1.66M
- Net Cash
- EUR 4.78M
- Net Cash Per Share
- EUR 1.06
- Tangible Book Value Per Share
- EUR 1.64
Margins
Gross margin is 90.45%, with operating margin of -14.60%, and net profit margin of -4.02%.
- Gross Margin
- 90.45%
- Operating Margin
- -14.60%
- Pretax Margin
- -3.68%
- Net Profit Margin
- -4.02%
- EBITDA Margin
- -4.65%
- EBIT Margin
- -4.81%
Analyst Forecast
The average price target for InnoCan Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -23.91%
- EPS Growth Forecast
- 44.31%
